A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones
- PMID: 39471817
- PMCID: PMC11856365
- DOI: 10.1016/j.cmet.2024.10.013
A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones
Abstract
Hepatic de novo lipogenesis (DNL) is a fundamental physiologic process that is often pathogenically elevated in metabolic disease. Treatment is limited by incomplete understanding of the metabolic pathways supplying cytosolic acetyl-CoA, the obligate precursor to DNL, including their interactions and proportional contributions. Here, we combined extensive 13C tracing with liver-specific knockout of key mitochondrial and cytosolic proteins mediating cytosolic acetyl-CoA production. We show that the mitochondrial pyruvate carrier (MPC) and ATP-citrate lyase (ACLY) gate the major hepatic lipogenic acetyl-CoA production pathway, operating in parallel with acetyl-CoA synthetase 2 (ACSS2). Given persistent DNL after mitochondrial citrate carrier (CiC) and ACSS2 double knockout, we tested the contribution of exogenous and leucine-derived acetoacetate to acetoacetyl-CoA synthetase (AACS)-dependent DNL. CiC knockout increased acetoacetate-supplied hepatic acetyl-CoA production and DNL, indicating that ketones function as mitochondrial-citrate reciprocal DNL precursors. By delineating a mitochondrial-cytosolic DNL substrate supply network, these findings may inform strategies to therapeutically modulate DNL.
Keywords: AACS; ACLY; ACSS2; ATP-citrate lyase; CiC; DNL; MPC; acetoacetyl-CoA synthetase; acetyl-CoA synthetase 2; de novo lipogenesis; liver; metabolomics; mitochondrial citrate carrier; mitochondrial pyruvate carrier; stable isotope tracers.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
References
-
- Lawitz EJ, Li KW, Nyangau E, Field TJ, Chuang JC, Billin A, Wang L, Wang Y, Huss RS, Chung C, et al. (2022). Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. J Lipid Res 63, 100250. 10.1016/j.jlr.2022.100250. - DOI - PMC - PubMed
-
- Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK, Westlin WF, Kapeller R, and Harwood HJ Jr. (2016). Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A 113, E1796–1805. 10.1073/pnas.1520686113. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- 851976/AHA/American Heart Association-American Stroke Association/United States
- T32 HL007344/HL/NHLBI NIH HHS/United States
- K01 DK133630/DK/NIDDK NIH HHS/United States
- P30 DK127984/DK/NIDDK NIH HHS/United States
- P30 CA086862/CA/NCI NIH HHS/United States
- T32 GM007337/GM/NIGMS NIH HHS/United States
- R01 DK128168/DK/NIDDK NIH HHS/United States
- R01 DK138664/DK/NIDDK NIH HHS/United States
- R01 DK104998/DK/NIDDK NIH HHS/United States
- T32 GM139776/GM/NIGMS NIH HHS/United States
- R01 DK078184/DK/NIDDK NIH HHS/United States
- T32 DK112751/DK/NIDDK NIH HHS/United States
- F32 DK116522/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
